Cargando...
Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines
BACKGROUND: Immune checkpoint inhibitors (ICIs) have led to a paradigm change in the management of metastatic renal cell carcinoma (mRCC). Prospective trials have focused on ICI treatment in the first or second line. The aim of this analysis is to evaluate the benefit of ICI across different treatme...
Gardado en:
| Publicado en: | ESMO Open |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Elsevier
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8261552/ https://ncbi.nlm.nih.gov/pubmed/34217917 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.esmoop.2021.100122 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|